

Short report

Open Access

Expression of nm23 in the spectrum of pre-invasive, invasive and metastatic breast lesions

Amanjit Bal*¹, Kusum Joshi¹, Rajesh Logasundaram¹, BD Radotra¹ and Rajinder Singh²

Address: ¹Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India and ²Department of General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Email: Amanjit Bal* - docaman5@hotmail.com; Kusum Joshi - kus_joshi@yahoo.com; Rajesh Logasundaram - rlsundaram@yahoo.com; BD Radotra - bishanradotra@hotmail.com; Rajinder Singh - pgimer@chd.nic.in

* Corresponding author

Published: 30 May 2008

Received: 4 March 2008

Diagnostic Pathology 2008, **3**:23 doi:10.1186/1746-1596-3-23

Accepted: 30 May 2008

This article is available from: <http://www.diagnosticpathology.org/content/3/1/23>

© 2008 Bal et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Nm23 protein is a metastasis suppressor protein, expressed in all tissues. Reduced Nm23 expression is related to a high incidence of lymph node and distant metastasis and poor prognosis in patients with cancers. The present study was done to analyze the expression of Nm23 using immunohistochemistry in non-neoplastic and neoplastic breast lesions.

Methods: Sections from 93 samples were studied and classified into non-proliferative breast lesion (13), fibroadenoma (7), proliferative breast lesion (13), carcinoma in situ (20), invasive carcinoma (23) and metastatic deposits in lymph nodes (17).

Results: Nm23 expression in these groups showed a progressive down regulation with increasing neoplastic transformation. On comparing the various groups, nm23 expression was significantly different between the various subgroups with greatest expression in non-proliferative lesions and least in metastatic deposits ($p < 0.050$).

Conclusion: It is concluded that the modulation of nm23 in a spectrum of breast lesions can be indicative of metastatic phenotype and help to predict the aggressiveness of disease.

Introduction

Breast cancer is the most common cancer in women of the developed countries with a persistently rising incidence [1]. Extensive research on diagnostic and therapeutic aspects has contributed little to decrease the mortality. This may be attributed to a relative lack of understanding of the natural history of disease and heterogeneity of pre invasive lesions [2].

Various biological makers known to be indicators of prognosis in breast cancer include growth factor receptors, oes-

trogen receptors, p53, bcl2, Her-2/neu oncogenes and proliferation indices like Ki67. But the most important prognostic factor remains the axillary lymph node status [3,4]. Majority of breast cancer patients succumb to metastatic disease. The molecular basis of the metastatic disease is not known, but activation or inactivation of multiple genes is involved in the various steps of tumor progression [5].

Non metastatic (nm23) gene is the one possible candidate that suppresses the metastatic phenotype [6]. It was first

identified by Steeg et al [7] in murine melanoma cells and inverse relationship between metastatic potential and nm23 RNA protein was found in four different metastatic models. Nm23 gene has been localized at chromosome 17q21 and two isoforms (nm23-H1 and nm23-H2) have been identified. Each isoform encodes 17 KD protein having non-specific nucleoside diphosphate kinase (NDPK) activity [8]. Reduced expression of nm23 in breast, hepatocellular and ovarian carcinoma correlates with increased metastatic potential [9-11]. On the contrary, in prostate and lung carcinomas, disease progression is associated with increased nm23 gene expression [12,13].

Breast carcinogenesis is known to be a multistep process and emerges through hyperplasia to atypical hyperplasia and carcinoma in situ [14,15]. Loss of heterozygosity at chromosome 16 and 17 has been observed in ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) showing that these genetic abnormalities take place before invasion[16].

The study has been designed to evaluate the expression of nm23/NDPK in breast epithelial lesions that are presumed to represent steps in progression of breast carcinoma.

Materials and methods

Formalin fixed paraffin-embedded sections of breast lesions were retrieved from the archives of the Department of Histopathology, PGIMER, Chandigarh. There were 93 samples in total; which were classified by the criteria of Dupont and Page[17,18] into six groups as: Non proliferative breast disease (fibrocystic disease, apocrine change and mild epithelial hyperplasia)-13 cases, fibroadenoma-7 cases, proliferative breast disease (moderate and florid hyperplasia)-13 cases, atypical hyperplasia and carcinoma in situ (ductal and lobular)-20 cases, invasive carcinoma(ductal and lobular)-23 cases, and metastatic deposits in lymph nodes-17 cases. None of these cases had received prior chemotherapy.

For immunohistochemistry avidin-biotin method was used. The antibody used was rabbit anti-human monoclonal antibody nm23 at 1:40 dilution (DAKO).

Quantification of immunostaining

The expression of the antigen was evaluated in a semi-quantitative manner as previously described by Bankfalvi et al [19]. Sections were scored based on two parameters: (a) Percentage of positively stained cells; no staining-0, <5% cells stained-1, 5-75% cells stained-2, >75% cells stained-3 (b) Intensity of staining; absent -0 mild-1, moderate-2, strong-3.

Multiplying the values of both parameters generated immunoreactivity scores and this ranged from 0 to 9.

Statistical analysis

ANOVA test was applied to compare scores between the groups.

Results

The results are summarized in table 1.

Nm23 expression in non-proliferative breast lesions

This group includes fibrocystic disease, apocrine change and mild epithelial hyperplasia (13 cases). Nm23 was strongly expressed in epithelial as well as stromal cells. Homogeneous staining pattern was observed in cytoplasm of both epithelial and myoepithelial cells (Fig. 1). Immunoreactivity score ranged from 4-9 (mean = 7.150, SD = 2.190). Scores were statistically significantly higher when compared with other groups (proliferative lesions p < 0.050, carcinoma in situ p < 0.001, invasive carcinoma p < 0.001 and lymph node metastasis p < 0.001).

Nm23 expression in fibroadenoma

Seven cases of fibroadenoma were studied. A homogeneous and strong nm23 expression approximating non-proliferative lesions was observed in epithelial and stromal cells (Fig. 2). Score ranged from 4-9 (mean = 7.860, SD = 2.030). Immunoreactivity scores were compared with other groups and the difference was statistically significant (proliferative lesions p < 0.002, carcinoma in situ p < 0.001, invasive carcinoma p < 0.001 and lymph node metastasis p < 0.001). No significant difference was found between fibroadenoma and non-proliferative lesions.

Table 1: Nm23 expression in spectrum of benign and malignant breast lesions

S.No	Group	No. of cases	Mean score (Range)	SD	COV	SE of mean
1	Non-proliferative lesions	13	7.150(4-9)	2.192	30.649	0.608
2	Fibroadenoma	7	7.860(4-9)	2.034	25.905	0.769
3.	Proliferative lesions	13	5.461(2-9)	1.664	30.469	0.461
4	Carcinoma in situ	20	4.104(2-6)	1.651	40.271	0.369
5.	Invasive carcinoma	23	2.871(0-6)	1.516	52.859	0.316
6.	Lymph node metastasis	17	1.241(0-6)	1.855	150.170	0.449

SD-Standard deviation, COV-coefficient of variation, SE-Standard error




Figure 1
Photomicrograph showing strong nm23 expression in epithelial cells in fibrocystic change (Nm23 immunostain).




Figure 3
Photomicrograph showing moderate nm23 expression in florid epithelial hyperplasia (Nm23 immunostain).

Nm23 expression in proliferative breast lesions

This group includes moderate and florid hyperplasia (13 cases). Homogeneous moderate staining for nm23 was noted in the hyperplastic areas with a score range of 2–9 (mean = 5.460, SD = 1.660) (Fig. 3). Scores varied significantly from scores of carcinoma in situ ($p < 0.005$), invasive carcinoma ($p < 0.001$) and lymph node metastasis ($p < 0.001$).




Figure 2
Photomicrograph showing strong nm23 expression in epithelial cells and a few stromal cells in fibroadenoma (Nm23 immunostain).

Nm23 expression in carcinoma in situ

Twenty cases of carcinoma in situ including one case of lobular carcinoma in situ showing areas of atypical ductal hyperplasia were studied. Weak to moderate immunoreactivity was noted in epithelial cells with score ranging from 2–6 (mean = 4.100, SD = 1.650). Carcinoma in situ had greater nm23 expression than invasive carcinoma ($p < 0.002$) and lymph node metastasis ($p < 0.001$). No significant difference was observed in staining intensity of comedo and non-comedo carcinoma in situ.

Nm23 expression in invasive carcinoma

This group includes 23 cases of invasive carcinoma. Most of these showed extremely reduced nm23 expression in tumour cells with score range of 0–6 (mean = 2.870, SD = 1.510) (Fig. 4). The scores varied significantly when compared with lymph node metastasis ($p < 0.001$). Periductal elastosis was strongly stained. There was no difference in staining intensity between ductal and lobular subtypes.

Nm23 expression in lymph node metastasis

Nm23 immunoreactivity was absent to weak in metastatic tumour cells (Fig. 5). The score range was 0–6 (mean = 1.240, SD = 1.850).

In this study there were 27 cases that showed spectrum of lesions ranging from normal to metastatic disease. There was a progressive down regulation of nm23 expression with neoplastic transformation; so that scores of 9 in non-proliferative breast disease decreased to 6 in carcinoma in situ, to 3 in invasive cancer and 0 in metastatic cancers.




Figure 4
Photomicrograph showing weak to absent nm23 expression in invasive ductal carcinoma cells (Nm23 immunostain).

Discussion

Oncogenes (C-erb2, C-myc, genes linked to 11q13, tumour suppressor genes (retinoblastoma gene, p53) and anti-metastatic gene (nm23) play important roles in breast cancer progression [20]. Several investigators have reported the probable inverse association of nm23 expression with disease prognosis and or metastasis [21]. Metastatic process involves activation and down regulation of multiple genes at each step of metastatic cascade. Though there have been conflicting reports of increased nm23 expression in solid tumours (breast, colon, cervix, melanoma) compared to the benign counterparts [22,23].




Figure 5
Photomicrograph showing absent nm23 expression in metastatic breast carcinoma. (Nm23 immunostain).

Recent studies, however, are more consistent with that of nm23 functioning as a metastatic suppressor gene.

Royds et al [24] studied expression of nm23 in a variety of breast lesions. All of their benign categories showed uniform epithelial cell staining. In in-situ category non-comedo DCIS were positive whereas the comedo variants were negative for the protein expression. They also found that nm23 negativity was significantly associated with worsening grade of ductal carcinoma and advancing lymph node stage. They concluded that nm23 protein expression decreases with advancing grade of breast lesions and the negativity in comedo variant of DCIS is a finding consistent with the fact that comedo histology is known to have higher likelihood of becoming invasive.

Several other genetic alterations have been found to be consistently associated with such tumour progression apart from nm23. These include the FHIT gene located at human chromosome 3p14.2, novel genes called mta1 (in rodents) or MTA1 (in humans), NES1, and the tumour suppressor gene maspin [25-29]

In the present study, our aim was to evaluate the modulation of nm23 expression in breast lesions as they progress from "normal" to "invasive cancer" through varying stages of "proliferative breast diseases". We detected the nm23 expression using immunohistochemistry and all the non-proliferative lesions strongly expressed the protein. Expression of nm23 was moderate in fibroadenoma, proliferative breast diseases and in carcinoma in-situ. In invasive carcinoma and metastatic diseases the nm23 expression was weak to absent. The difference in staining in various subgroups was also statistically significant. Thus our results show that there is down regulation of nm23 expression with the progress of neoplastic transformation. These results implicate that lack of nm23 expression in early lesions may be predictive of progression to invasive carcinoma. Though the findings in our study are in concordance with that of Royds et al [24], we found no difference in staining pattern between comedo versus non-comedo variants of DCIS. Also no difference in staining pattern between the morphologic variants of carcinoma (ductal/lobular) was detected in the present study.

Nm23 expression has been widely studied in various cancers and with their relation to staging and prognosis. There are very few studies in literature which have systematically studied the expression of this protein in both benign and malignant counterparts as spectrum. Our study is one such attempt and the results implicate that lack of nm23 expression in early lesions may be predictive of progression to invasive carcinoma and thus could be helpful in predicting the aggressiveness of the disease.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ABa and KJo participated in selecting cases, carrying out immunohistochemistry, interpretation of results, and writing of the manuscript, RLo and BRa participated in the histopathological diagnosis, and editing of the manuscript, RSi provided the clinical details of the patients. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by financial grant from ICMR (Indian council of medical research)

References

- Garfinkel L, Boring CC, Health CW: **Changing trends-An overview of breast cancer incidence and mortality.** *Cancer* 1994, **74(suppl)**:222-27.
- Welling SR, Jensen HM, Marcum RG: **An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.** *J Natl Cancer Inst* 1975, **155(2)**:231-73.
- Stoll BA: **Permalignant breast lesions: role for biological markers in predicting progression to cancer.** *Eur J Cancer* 1999, **35**:693-97.
- Hermesen MAJA, Baak JPA, Meijer GA, Weiss JM, Walboomers JVV, Snijders PJF, Duet PJV: **Genetic analysis of 53 lymph-node negative breast carcinoma by CGH and relation to clinical, pathological, morphometric and DNA cytometric prognostic factors.** *Pathol* 1998, **186**:356-62.
- Fidler IJ, Radinsky R: **Editorial: Genetic control of Cancer metastasis.** *J Natl Cancer Inst* 1990, **82**:166-68.
- Evans CVW: **Genetic basis for metastasis.** *Cell Biol Int Rep* 1991, **15**:1175-81.
- Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME: **Evidence for a novel gene associated with low tumor metastatic potential.** *J Natl Cancer Inst* 1998, **80(3)**:200.
- Mac Donald NJ, De La Rosa A, Steeg PS: **The potential role of nm23 in cancer metastasis and cellular differentiation.** *Eur J Cancer* 1995, **31A**:1096-100.
- Bevilacqua G, Sobel ME, Liotta LA, Steeg PS: **Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinoma with lymph-node involvement and other histopathological indicators of high metastatic potential.** *Cancer Res* 1989, **49**:5185-90.
- Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K, Ishii N, Kimura N, Nagataki S: **Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product.** *J Natl Cancer Inst* 1992, **84**:1349-54.
- Mandai M, Konishi I, Kashiyama M, Mori T, Arai S, Tashiro H, Okamura H, Nomura H, Hiai H, Fukumoto M: **Expression of metastasis related nm23-H1 and nm23-H2 gene in ovarian carcinomas: correlation with clinicopathology, EGFR, C-erb B-2 and C-erb B-3 gene and sex steroid receptor expression.** *Cancer Res* 1994, **54**:1825-30.
- Igawa M, Ruskstalis DB, Tanabe T: **High levels of nm23 expression are related to cell proliferation in human prostate cancer.** *Cancer Res* 1994, **54**:1313-18.
- Engel M, Theisinger B, Seib T: **High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous cell lung carcinoma are associated with poor differentiation and advanced tumor stages.** *Int J Cancer* 1993, **55**:375-79.
- Lakhani SR: **The transition from hyperplasia to invasive carcinoma breast.** *J Pathol* 1999, **187**:272-78.
- Page DL, Rogers LW: **Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia.** *Hum Pathol* 1992, **23**:1095-97.
- Lakhani SR, Collins N, Sloane JP, Stratton MR: **Loss of heterozygosity in lobular carcinoma in situ of the breast.** *Clin Mol Pathol* 1995, **48(2)**:M74-78.
- Dupont WD, Page DL: **Risk factors for breast cancer in women with proliferative breast disease.** *N Engl J Med* 1985, **312**:146-51.
- Page DL, Dupont WD: **Premalignant conditions and markers of elevated risk in breast cancer and their management.** *Surg Clin North Am* 1990, **70**:831-51.
- Bankfalvi A, Terpe HJ, Breukelmann D, et al.: **Immunophenotypic and prognostic analysis of E-Cadherin and B Catenin expression during breast carcinogenesis and tumor progression a comparative study with CD44.** *Histopathology* 1999, **34**:25-34.
- Yamashita H, Kobayashi S, Lwase H, Itoh Y, Kuzushima T, Iwata H, Itoh K, Naito A, Yamashita I, Masaoka A: **Analysis of oncogenes and tumor suppressor genes in human breast cancer.** *Jpn J Cancer Res* 1993, **84**:871-78.
- Tokunaga Y, Urano T, Furokawa K, Kondo H, Kanamatsu T, Shiku II: **Reduced expression of nm23 H1, but not nm23 H2, is concordant with the frequency of lymph node metastasis of human breast cancer.** *Int J Cancer* 1993, **55**:66-71.
- Lacombe ML, Sastre-Garau X, Lascu I, Vonica A, Wallet V, Thiery JP, Véron MI: **Overexpression of nucleoside diphosphate kinase (nm23) in solid tumors.** *Eur J Cancer* 1991, **27**:1302-07.
- Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, Reynolds CP, Seeger RC, Lottspeich F, Strahler JR: **High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification.** *J Clin Invest* 1991, **88(1)**:341-45.
- Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB: **Nm23 protein expression in ductal in situ and invasive human breast carcinoma.** *J Natl Cancer Inst* 1993, **85(9)**:727-31.
- Gatalica Z, Lele SM, Rampy BA, Norris BA: **The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.** *Cancer* 2000, **88(15)**:1378-83.
- Nicolson GL: **Breast cancer metastasis-associated genes: role in tumor progression to the metastatic state.** *Biochem Soc Symp* 1998, **63**:231-43.
- Yunes MJ, Neuschatz AC, Bornstein LE, Naber SP, Band V, Wazer DE: **Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.** *Int J Radiat Oncol Biol Phys* **56(3)**:653-57. 2003 Jul 1
- Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat WW: **Expression and regulation of tumor suppressor gene maspin in breast cancer.** *Clin Breast Cancer* 2002, **3**:281-87.
- Umekita Y, Yoshida H: **Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.** *Histopathology* 2003, **42**:541-45.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

